Sandro De Falco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5506857/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis. International Journal of Molecular Sciences, 2021, 22, 3896.	1.8	2
2	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. International Journal of Molecular Sciences, 2021, 22, 4404.	1.8	12
3	VEGFR1 signaling in retinal angiogenesis and microinflammation. Progress in Retinal and Eye Research, 2021, 84, 100954.	7.3	123
4	Long Non-coding RNA T-UCstem1 Controls Progenitor Proliferation and Neurogenesis in the Postnatal Mouse Olfactory Bulb through Interaction with miR-9. Stem Cell Reports, 2020, 15, 836-844.	2.3	8
5	Generation and testing of engineered multimeric Fabs of trastuzumab. International Journal of Biological Macromolecules, 2020, 164, 4516-4531.	3.6	2
6	Synergistic interactions of PIGF and VEGF contribute to blood-retinal barrier breakdown through canonical NFIºB activation. Experimental Cell Research, 2020, 397, 112347.	1.2	8
7	α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells. Scientific Reports, 2020, 10, 9619.	1.6	27
8	Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization. International Journal of Molecular Sciences, 2020, 21, 410.	1.8	8
9	Synthetic Peptide Libraries: From Random Mixtures to In Vivo Testing. Current Medicinal Chemistry, 2020, 27, 997-1016.	1.2	9
10	Placental growth factor regulates the generation of TH17 cells to link angiogenesis with autoimmunity. Nature Immunology, 2019, 20, 1348-1359.	7.0	34
11	Aflibercept regulates retinal inflammation elicited by high glucose via the PIGF/ERK pathway. Biochemical Pharmacology, 2019, 168, 341-351.	2.0	57
12	Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene, 2018, 37, 627-637.	2.6	53
13	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmologica, 2018, 96, e1-e9.	0.6	60
14	Targeting VEGF receptors with non-neutralizing cyclopeptides for imaging applications. Amino Acids, 2018, 50, 321-329.	1.2	6
15	Full Functional Knockout of Placental Growth Factor by Knockin with an Inactive Variant Able to Heterodimerize with VEGF-A. Cell Reports, 2018, 23, 3635-3646.	2.9	10
16	Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 2018, 9, 25630-25646.	0.8	5
17	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. British Journal of Cancer, 2017, 116, 1425-1435.	2.9	76
18	Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper. European Journal of Ophthalmology, 2017, 27, 627-639.	0.7	22

SANDRO DE FALCO

#	Article	IF	CITATIONS
19	Hypoxia activates placental growth factor expression in lymphatic endothelial cells. Oncotarget, 2017, 8, 32873-32883.	0.8	26
20	Human lgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduction and Targeted Therapy, 2016, 1, .	7.1	30
21	Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduction and Targeted Therapy, 2016, 1, .	7.1	23
22	Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction. PLoS ONE, 2015, 10, e0140697.	1.1	19
23	The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy. International Journal of Biochemistry and Cell Biology, 2015, 64, 185-189.	1.2	37
24	Placental Growth Factor-1 and -2 Induce Hyperplasia and Invasiveness of Primary Rheumatoid Synoviocytes. Journal of Immunology, 2015, 194, 2513-2521.	0.4	22
25	Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget, 2015, 6, 10563-10576.	0.8	24
26	Antiangiogenesis therapy: an update after the first decade. Korean Journal of Internal Medicine, 2014, 29, 1.	0.7	53
27	Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions. Epigenetics, 2014, 9, 600-610.	1.3	36
28	Powerful tumor cell growth-inhibiting activity of a synthetic derivative of atractyligenin: Involvement of PI3K/Akt pathway and thioredoxin system. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1135-1144.	1.1	7
29	L-Proline Induces a Mesenchymal-like Invasive Program in Embryonic Stem Cells by Remodeling H3K9 and H3K36 Methylation. Stem Cell Reports, 2013, 1, 307-321.	2.3	80
30	Bioassay-Guided Isolation of Proanthocyanidins with Antiangiogenic Activities. Journal of Natural Products, 2013, 76, 29-35.	1.5	24
31	The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells. Biology Open, 2013, 2, 1070-1077.	0.6	17
32	Retinal angiogenesis suppression through small molecule activation of p53. Journal of Clinical Investigation, 2013, 123, 4170-4181.	3.9	24
33	Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis, 2012, 224, 51-57.	0.4	51
34	The discovery of placenta growth factor and its biological activity. Experimental and Molecular Medicine, 2012, 44, 1.	3.2	319
35	Inhibition of Choroidal and Corneal Pathologic Neovascularization by <i>Plgf1-de</i> Gene Transfer. , 2012, 53, 7989.		16
36	An Automated High Throughput Screening-Compatible Assay to Identify Regulators of Stem Cell Neural Differentiation. Molecular Biotechnology, 2012, 50, 171-180.	1.3	14

SANDRO DE FALCO

#	Article	IF	CITATIONS
37	Anti-angiogenic Activity Evaluation of Secondary Metabolites from <i>Calycolpus Moritzianus</i> Leaves. Natural Product Communications, 2011, 6, 1934578X1100600.	0.2	0
38	Branched Peptides for the Modulation of Protein-Protein Interactions: More Arms are Better than One?. Current Medicinal Chemistry, 2011, 18, 2429-2437.	1.2	9
39	Control of embryonic stem cell metastability by l-proline catabolism. Journal of Molecular Cell Biology, 2011, 3, 108-122.	1.5	66
40	The Biflavonoid Amentoflavone Inhibits Neovascularization Preventing the Activity of Proangiogenic Vascular Endothelial Growth Factors. Journal of Biological Chemistry, 2011, 286, 19641-19651.	1.6	34
41	A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. American Journal of Cancer Research, 2011, 1, 265-274.	1.4	8
42	Anti–neuropilinâ€1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis and Rheumatism, 2010, 62, 179-190.	6.7	51
43	A Small Synthetic Cripto Blocking Peptide Improves Neural Induction, Dopaminergic Differentiation, and Functional Integration of Mouse Embryonic Stem Cells in a Rat Model of Parkinson's Disease Â. Stem Cells, 2010, 28, 1326-1337.	1.4	40
44	Propionyl- <scp> </scp> -Carnitine Improves Postischemic Blood Flow Recovery and Arteriogenetic Revascularization and Reduces Endothelial NADPH-Oxidase 4–Mediated Superoxide Production. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 426-435.	1.1	53
45	A Placental Growth Factor Variant Unable to Recognize Vascular Endothelial Growth Factor (VEGF) Receptor-1 Inhibits VEGF-Dependent Tumor Angiogenesis via Heterodimerization. Cancer Research, 2010, 70, 1804-1813.	0.4	54
46	Flt-1 expression influences apoptotic susceptibility of vascular smooth muscle cells through the NF-îºB/IAP-1 pathway. Cardiovascular Research, 2010, 85, 214-223.	1.8	15
47	Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7137-7142.	3.3	132
48	Role of placenta growth factor and its receptor fltâ€1 in rheumatoid inflammation: A link between angiogenesis and inflammation. Arthritis and Rheumatism, 2009, 60, 345-354.	6.7	90
49	Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1. Journal of Biological Chemistry, 2008, 283, 34250-34259.	1.6	33
50	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	3.2	139
51	Competitive ELISA-Based Screening of Plant Derivatives for the Inhibition of VEGF Family Members Interaction with Vascular Endothelial Growth Factor Receptor 1. Planta Medica, 2008, 74, 401-406.	0.7	11
52	Chemical synthesis of mouse cripto CFC variants. Proteins: Structure, Function and Bioinformatics, 2006, 64, 779-788.	1.5	12
53	Corneal avascularity is due to soluble VEGF receptor-1. Nature, 2006, 443, 993-997.	13.7	605
54	Plgf â^'/â^' eNos â^'/â^' mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB Journal, 2006, 20, 970-972.	0.2	50

SANDRO DE FALCO

#	Article	IF	CITATIONS
55	Ribonucleases and Angiogenins from Fish. Journal of Biological Chemistry, 2006, 281, 27454-27460.	1.6	36
56	The C. elegans pvfâ€1 gene encodes a PDGF/VEGFâ€like factor able to bind mammalian VEGF receptors and to induce angiogenesis. FASEB Journal, 2006, 20, 227-233.	0.2	53
57	Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor. Journal of Biological Chemistry, 2004, 279, 43929-43939.	1.6	44
58	Placenta growth factor is not required for exercise-induced angiogenesis. Angiogenesis, 2004, 7, 277-284.	3.7	33
59	Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. British Journal of Cancer, 2004, 90, 833-837.	2.9	114
60	Structure and Function of Placental Growth Factor. Trends in Cardiovascular Medicine, 2002, 12, 241-246.	2.3	118
61	N-terminal myristylation of HBV preS1 domain enhances receptor recognition. Chemical Biology and Drug Design, 2001, 57, 390-400.	1.2	26
62	Cloning and Expression of a Novel Hepatitis B Virus-binding Protein from HepG2 Cells. Journal of Biological Chemistry, 2001, 276, 36613-36623.	1.6	69
63	Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nature Biotechnology, 2000, 18, 735-739.	9.4	62
64	An Expression System for the Single-Step Production of Recombinant Human Amidated Calcitonin. Protein Expression and Purification, 1996, 7, 347-354.	0.6	11
65	Trascrizione e traduzionein vitro di un cDNA completo codificante per la proteina ribosomale umana Lia. Rendiconti Lincei, 1993, 4, 83-88.	1.0	0
66	Human L7a ribosomal protein: sequence, structural organization, and expression of a functional gene. Gene, 1993, 126, 227-235.	1.0	23
67	Lipoprotein-mediated delivery of antisense oligonucleotides. Journal of Controlled Release, 1992, 21, 213-214.	4.8	0
68	Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Research, 1991, 19, 4695-4700.	6.5	148
69	GENE MODULATION BY TUMOR PROMOTERS. , 1987, , 101-116.		2